KaydedilenlerDerginizi ekleyin

Dergiler / İstanbul Kuzey Klinikleri / 2017 / Cilt: 4 - Sayı: 3

Hallucination: A rare complication of levetiracetam theraphy

Seher ERDOGAN
Mehmet BOSNAK
Sayfa
266–269
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The purpose of this report was to remind physicians that hallucinations are one of the rare complications of levetiracetam.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Levetiracetam is a new antiepileptic drug.
📊
Temel Bulgular & Veri:Phenytoin therapy in a 10-year-old boy with convulsions was discontinued following cardiac rhythm impairment.
💡
Sonuç & Katkı:The purpose of this report was to remind physicians that hallucinations are one of the rare complications of levetiracetam.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Levetiracetam is a new antiepileptic drug. In addition to epilepsy, it is also used for treating anxiety disorders and dystonia as well as tardive dyskinesia associated with the use of levodopa and neuroleptic drugs. Phenytoin therapy in a 10-year-old boy with convulsions was discontinued following cardiac rhythm impairment. The patient was then started on levetiracetam. However, visual and auditory hallucinations were observed on the 1st day of levetiracetam therapy. Levetiracetam was discontinued and replaced with sodium valproate, and the hallucinations resolved. The purpose of this report was to remind physicians that hallucinations are one of the rare complications of levetiracetam.

🔖

Bu Makaleye Atıf Yap

ERDOGAN, S., BOSNAK, M. (2022). Hallucination: A rare complication of levetiracetam theraphy. İstanbul Kuzey Klinikleri, Cilt: 4 - Sayı: 3, 266–269. https://ajindex.com/articles/551595

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007;48:2322-6
  2. Grünewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia 2005;46(Suppl 9):154-60
  3. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002;136:659-72
  4. Wheless JW, Ng YT. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 2002;17:413-5
  5. Idris S, Hacıfazlıoğlu N, Yılmaz Y. The efficacy of the levetiracetam in children with intractable epilepsy. Epilepsi 2011;17:1-8
  6. Coppola G, Mangano S, Tortorella G, Pelliccia A, Fels A, Romano A, et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 2004;59:35-42
  7. Callenbach PM, Arts WF, ten Houten R, Augustijn P, Gunning WB, Peeters EA, et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Eur J Paediatr Neurol 2008;12:321-7
  8. Peake D, Mordekar S, Gosalakkal J, Mukhtyar B, Buch S, Crane J, et al. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Seizure 2007;16:185-9 9. Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004;13:55-7
  9. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001;42:1611-3
  10. Halma E, de Louw AJ, Klinkenberg S, Aldenkamp AP, IJff DM, Majoie M. Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. Seizure 2014;23:685-91
  11. Shakya DR, Dutta A, Gautam R. Hallucination in a seizure patient using levetiracetam: a case report. Case Rep Med 2012;2012:706243
  12. Aksoy D, Cevik B, Kurt S, Pekdas E, Solmaz V. Hypokalemia and hypomagnesaemia related to levetiracetam use. J Clin Neurosci 2014;21:1989-90
  13. Eleni K. Dress syndrome induced by levetiracetam. J Eur Acad Dermatol Venereol 2015;29:377-8.